Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients

Transplantation

Volumn 88, Issue 10, 2009, Pages 1208-1213

  Lim, Wai H ^a,b   Chang, Sean H ^b   Chadban, Steve J ^b,c   Campbell, Scott B ^b,d   Dent, Hannah ^b,e   Russ, Graeme R ^b,f   McDonald, Stephen P ^b,f  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b ANZDATA Registry   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

ANZDATA registry.; Graft survival; IL 2 receptor antibody; Live donor kidney transplant; Rejection

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INCIDENCE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE;

ADULT; ANTIBODIES; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PATIENT SELECTION; RECEPTORS, INTERLEUKIN-2; REGISTRIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 73849131794     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bb4339     Document Type: Article

References (19)

1. Wolfe R, Ashby V, Milford E, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
2. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lympho-proliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
3. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 2005; 56: 71.
4. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193.
5. Chang S, Russ G, Chadban S, et al. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005. Nephrology (Carlton) 2008; 13: 171.
6. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: A comparative review. BioDrugs 2005; 19: 39.
7. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: A review. Clin Transplant 2005; 19: 705.
8. Webster A, Playford E, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 2004; 77: 166.
9. Keown P, Balshaw R, Khorasheh S, et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs 2003; 17: 271.
10. Levey A, Bosch J, Lewis J, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
11. Kahan B, Rajagopalan P, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basilix-imab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67: 276.
12. Lawen J, Davies E, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37.
13. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261.
14. Sheashaa H, Bakr M, Ismail A, et al. Basiliximab induction therapy for live donor kidney transplantation: A long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008; 12: 376.
15. McDonald S, Russ G, Campbell S, et al. Kidney transplant rejection in Australia and New Zealand: Relationships between rejection and graft outcome. Am J Transplant 2007; 7: 1201.
16. Qvist E, Their M, Krogerus L, et al. Early treatment of acute rejections gives favorable long-term function after renal transplantation in small children. Pediatr Transplant 2007; 11: 895.
17. Siddiqi N, McBride M, Hariharan S. Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/ OPTN database analysis. Kidney Int 2004; 65: 1906.
18. Chapman T, Keating G. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003; 63: 2803.
19. Keown P, Balshaw R, Krueger H, et al. Economic analysis of basiliximab in renal transplantation. Transplantation 2001; 71: 1573.